Hepatitis News : Targeting Hidden HIV: Research Group Licenses New Prostratin Technology
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis News » February 2010


emailprint

February 8, 2010

Targeting Hidden HIV: Research Group Licenses New Prostratin Technology

Los Angeles-based AIDS Research Alliance (ARA) has been granted exclusive rights to novel technology that will allow researchers to synthesize prostratin, a natural compound believed to target HIV hiding in inactive CD4 cells in the body, according to a February 8 press release. The technology, developed by researchers at Stanford University, will allow ARA to further develop prostratin without having to collect it from natural resources-an expensive and cumbersome process. 

Prostratin was initially isolated by the National Cancer Institute (NCI) in 1992 as the active constituent of extracts of the tropical plant Homalanthus nutans—whose common names include native poplar and bleeding heart. Naturally found in the Samoan rainforest, the bark of the plant is used in Western Samoa to treat viral diseases such as hepatitis.

In 2001, ARA applied to the NCI for the exclusive license to develop prostratin as an HIV drug. Initial studies conducted by the NCI and ARA indicated that prostratin activates latent HIV in cells, forcing them to produce new virus. This is good news because latent "reservoirs" of HIV hidden throughout the body—including the brain, lymphoid tissue and genital tract—escape the reach of current HIV drugs and the immune system and, thus, remain a major stumbling block to the eradication of HIV. The hope is that if the latent HIV can be activated, then it can be destroyed.

Research has been hampered because prostratin is difficult to obtain, particularly in the quantities needed for practical lab work. The yield of prostratin from H. nutans is low and highly variable; the plant supply is limited; and it's difficult to isolate the compound. What's more, harvesting wild plants, especially in Samoa, also could cause ecological damage. 

The ability to manufacture synthetic prostratin, using a technique developed by Stanford chemist Paul Wender, PhD, and his colleagues, and detailed in a May 2008 issue of Science, has helped researchers overcome these obstacles. 

The method developed my Wender's group uses a renewable resource, croton oil, made from the seeds of Croton tiglium, a small tree cultivated in Asia. Wender's team derived phorbol from the croton oil and then converted it into the structure of prostratin. 

"Wender's genius removes a major hurdle to the therapeutic development of this promising compound," said Carolyn H. Carlburg, president of ARA. The ability to produce prostratin synthetically will significantly reduce future costs, making prostratin a more viable drug candidate, she said.

"When used in combination with existing antiretroviral drugs, prostratin may one day help treating physicians eradicate all virus from the body—a feat not yet possible using existing therapies," stated Stephen J. Brown, MD, medical director at ARA.

Search: Prostratin, AIDS Research Alliance, Stanford, Wender, reservoirs, latent HIV, Homalanthus nutans, Croton tiglium, croton oil, Samoa, native poplar, bleeding heart


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Should Medicaid limit access to new hep C drugs?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.